A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
28
04
2020
pubmed:
14
5
2020
medline:
22
6
2021
entrez:
14
5
2020
Statut:
ppublish
Résumé
FLC is a complex cancer with many implicated oncogenic pathways. Single or dual targeting does not appear to alter the natural history of the cancer, and novel therapeutics are needed. Estrogen deprivation therapy with letrozole and leuprolide, alone or in combination with the mTOR inhibitor, everolimus, did not demonstrate clinical activity in advanced fibrolamellar carcinoma. The study drugs were well tolerated when administered as single agents or in combination in this patient population. This study demonstrates that, despite the rarity of FLC, multicenter therapeutic clinical trials are feasible and support the value of this consortium. Fibrolamellar carcinoma (FLC) is an uncommon malignancy in young people and is sometimes associated with pregnancy and oral contraceptive use. Immunohistochemical staining and genetic profiling of FLC tumor specimens have revealed aromatase overexpression. The overexpression of mTOR and S6 kinase has been noted in 25% of FLC. On the basis of interaction between estrogen and the PI3K/Akt/mTOR pathway, we hypothesized that suppression of estrogen and mTOR signaling could have antineoplastic activity in FLC. Patients were randomized to arm A (everolimus), arm B (letrozole/leuprolide; estrogen deprivation therapy [EDT]), or arm C (everolimus/letrozole/leuprolide). Upon disease progression, patients in arm A or B could proceed to part 2 (everolimus/letrozole/leuprolide). The primary endpoint was progression-free survival (PFS) at 6 months (PFS6) assessed using a Simon's minimax two-stage design, hypothesizing an improvement in PFS6 from 40% to 64% with the study regimen. Twenty-eight patients were enrolled. An unplanned analysis was performed because of perceived concern for lack of efficacy. Stable disease was observed in 9 of 26 evaluable patients (35%). PFS6 was 0%. Median overall survival (OS) was 12.4 months (95% confidence interval [CI], 7.4-20.9) for the whole study cohort. Grade 3 adverse events in ≥10% of patients were nausea (11%), vomiting (11%), anemia (11%), elevated aspartate transaminase (AST; 32%), alanine transaminase (ALT; 36%), and alkaline phosphatase (14%). All 28 patients experienced an event for PFS outcome, and four deaths were due to disease progression. Neither EDT nor mTOR inhibition improved outcomes in FLC. Other treatment strategies are needed.
Sections du résumé
LESSONS LEARNED
FLC is a complex cancer with many implicated oncogenic pathways. Single or dual targeting does not appear to alter the natural history of the cancer, and novel therapeutics are needed. Estrogen deprivation therapy with letrozole and leuprolide, alone or in combination with the mTOR inhibitor, everolimus, did not demonstrate clinical activity in advanced fibrolamellar carcinoma. The study drugs were well tolerated when administered as single agents or in combination in this patient population. This study demonstrates that, despite the rarity of FLC, multicenter therapeutic clinical trials are feasible and support the value of this consortium.
BACKGROUND
Fibrolamellar carcinoma (FLC) is an uncommon malignancy in young people and is sometimes associated with pregnancy and oral contraceptive use. Immunohistochemical staining and genetic profiling of FLC tumor specimens have revealed aromatase overexpression. The overexpression of mTOR and S6 kinase has been noted in 25% of FLC. On the basis of interaction between estrogen and the PI3K/Akt/mTOR pathway, we hypothesized that suppression of estrogen and mTOR signaling could have antineoplastic activity in FLC.
METHODS
Patients were randomized to arm A (everolimus), arm B (letrozole/leuprolide; estrogen deprivation therapy [EDT]), or arm C (everolimus/letrozole/leuprolide). Upon disease progression, patients in arm A or B could proceed to part 2 (everolimus/letrozole/leuprolide). The primary endpoint was progression-free survival (PFS) at 6 months (PFS6) assessed using a Simon's minimax two-stage design, hypothesizing an improvement in PFS6 from 40% to 64% with the study regimen.
RESULTS
Twenty-eight patients were enrolled. An unplanned analysis was performed because of perceived concern for lack of efficacy. Stable disease was observed in 9 of 26 evaluable patients (35%). PFS6 was 0%. Median overall survival (OS) was 12.4 months (95% confidence interval [CI], 7.4-20.9) for the whole study cohort. Grade 3 adverse events in ≥10% of patients were nausea (11%), vomiting (11%), anemia (11%), elevated aspartate transaminase (AST; 32%), alanine transaminase (ALT; 36%), and alkaline phosphatase (14%). All 28 patients experienced an event for PFS outcome, and four deaths were due to disease progression.
CONCLUSION
Neither EDT nor mTOR inhibition improved outcomes in FLC. Other treatment strategies are needed.
Identifiants
pubmed: 32400000
doi: 10.1634/theoncologist.2020-0367
pmc: PMC7648371
doi:
Substances chimiques
Estrogens
0
Letrozole
7LKK855W8I
Everolimus
9HW64Q8G6G
Leuprolide
EFY6W0M8TG
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
925-e1603Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© AlphaMed Press; the data published online to support this summary are the property of the authors.
Références
Sci Rep. 2017 Mar 17;7:44653
pubmed: 28304380
Clin Cancer Res. 2008 May 1;14(9):2673-80
pubmed: 18451231
Cancer. 2003 Apr 15;97(8):2006-12
pubmed: 12673731
Hum Pathol. 2007 Apr;38(4):639-44
pubmed: 17367606
Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):E5916-25
pubmed: 26489647
Clin Cancer Res. 2004 Dec 15;10(24):8421-5
pubmed: 15623621
Science. 2014 Feb 28;343(6174):1010-4
pubmed: 24578576
Hepatology. 2018 Jul;68(1):384-386
pubmed: 29473972
Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):13076-13084
pubmed: 29162699
Pediatrics. 1988 Sep;82(3):379-82
pubmed: 2841641
World J Gastrointest Surg. 2014 Jun 27;6(6):107-11
pubmed: 24976904
Cancer. 2006 Mar 15;106(6):1331-8
pubmed: 16475212
Dig Dis Sci. 2020 Feb 12;:
pubmed: 32052215
Oncologist. 2020 Dec;25(12):e1837-e1845
pubmed: 32154962
Gastrointest Cancer Res. 2013 Jan;6(1):3-9
pubmed: 23505572
Hepatology. 2004 Mar;39(3):798-803
pubmed: 14999699
Mod Pathol. 2015 Jan;28(1):103-10
pubmed: 24925055
J Clin Endocrinol Metab. 1998 May;83(5):1797-800
pubmed: 9589695
J Reprod Med. 2005 Aug;50(8):633-7
pubmed: 16220774
Nat Clin Pract Oncol. 2008 Sep;5(9):531-42
pubmed: 18607391
J Clin Oncol. 2003 Feb 1;21(3):421-7
pubmed: 12560429
HPB (Oxford). 2003;5(3):191-3
pubmed: 18332985
Case Rep Oncol. 2012 Jan;5(1):169-72
pubmed: 22666208